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Abstract
Background: The pathophysiological significance of variable region glycosylation of autoantibodies is still unclear.
In the current study, the influence of the variable region N-linked oligosaccharides on the reactivity of three
autoantibody specificities was investigated with Sambucus nigra agglutinin (SNA), which mainly binds to
oligosaccharides with terminal a2, 6-linked sialic acid on the variable region of IgG.
Methods: Twenty-seven patients with serum positive anti-neutrophil cytoplasmic autoantibodies (ANCA) against
myeploperoxidase (MPO) or proteinase 3 (PR3), or autoantibodies against glomerular basement membrane (GBM)
were included. Total IgG was isolated and separated into non-SNA-binding and SNA-binding fractions with SNA
affinity chromatography. Antigen-specific IgG was purified by immunoaffinity chromatography.
Results: At the same concentration of IgG, the antigen binding level of non-SNA-binding IgG was significantly
lower than that of SNA-binding IgG for MPO-ANCA (absorbance value at 405 nm, 0.572 ± 0.590 vs. 0.962 ± 0.670, P
< 0.001) and for PR3-ANCA (0.362 ± 0.530 vs. 0.560 ± 0.531, P = 0.003). The antigen binding level of non-SNA-
binding IgG was significantly higher than that of SNA-binding IgG for anti-GBM antibodies (1.301 ± 0.594 vs. 1.172
± 0.583, P = 0.044). The level of variable region glycosylation of total IgG was significantly lower than that of
affinity-purified MPO-ANCA (1.021 ± 0.201 vs. 1.434 ± 0.134, P = 0.004). The level of variable region glycosylation of
total IgG was significantly higher than that of affinity-purified anti-GBM antibodies (1.034 ± 0.340 vs. 0.734 ± 0.333,
P = 0.007). The SNA-binding fraction of MPO-ANCA-containing IgG and PR3-ANCA-containing IgG induced higher
levels of neutrophil oxygen radical production than the corresponding non-SNA-binding fractions (P < 0.001 and P
= 0.043, respectively). The level of variable region glycosylation of affinity-purified MPO-ANCA was higher in active
AAV than the same patients in remission (P = 0.001).
Conclusion: Characteristics of variable region glycosylation of ANCA and anti-GBM antibodies were different from
that of total IgG, which might influence the antigen-binding ability of these antibodies. Variable region
glycosylation of ANCA might influence the effect of ANCA-induced neutrophils respiratory burst.
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Anti-neutrophil cytoplasmic antibody (ANCA)-asso-
ciated vasculitides (AAV) comprise granulomatosis with
polyangiitis [GPA, previously termed Wegener’sg r a n u -
lomatosis (WG)], microscopic polyangiitis (MPA),
Churg-Strauss syndrome (CSS) and renal-limited vascu-
litis (RLV). ANCAs comprise a group of antoantibodies
directed against constituents of granules of neutrophils
and lysosomes of monocytes [1]. Proteinase-3 (PR3) and
myeloperoxidase (MPO) are the two most important
target antigens of ANCAs. In about 4-14% of AAV
patients, co-existence of ANCA with anti-glomerular
basement membrane (GBM) autoantibodies, directed
against the noncollagenous (NC1) domain of a3c h a i n
of type IV collagen (a3(IV)NC1) has been reported [2,3].
IgGs are known to vary in the extent of glycosylation
at the highly conserved N-glycosylation sites of the frag-
ment crystallizable (Fc) part. Hyposialylation and hypo-
glycosylation of serum total IgG-Fc has been reported in
AAV [4-6]. Such changes could influence the pathoge-
netic potential of ANCA [7] but seem to have little, if
any, effect on the antigen-binding ability of ANCA [8].
Of note, 15-20% of human IgG molecules bear N-linked
oligosaccharides in the fragment antigen binding (Fab)
part, depending on the type of variable chain amino
acids [9-12]. Since there is no conserved N-linked oligo-
saccharide site in the constant domain, the N-linked oli-
gosaccharide in the IgG-Fab is actually attached in the
variable regions of the light (L) and/or heavy (H) chains
[13-17]. Unlike glycosylation of IgG-Fc, N-linked oligo-
saccharides addition to the Fab region might influence
the antigen-binding ability of antibodies [18]. Therefore,
we hypothesized that there should be some changes of
the variable region glycosylation of ANCA and anti-
GBM autoantibodies during antibody affinity
maturation.
Sambucus nigra agglutinin (SNA) directed against oli-
gosaccharides with terminal a2, 6-linked sialic acid [19]
has been shown to bind strongly to Fab glycans but not
to Fc glycans of native IgG [20-24]. In contrast to the
Fc glycans, the Fab glycans have been found to be fully
sialylated [25,26], allowing us to investigate the charac-
teristics of variable region glycosylation of ANCA and
anti-GBM autoantibodies with SNA.
Methods
Patients and samples
Plasma exchange fluid from 27 consecutive patients who
received plasma exchange treatment at initial onset of
active disease, in Peking University First Hospital, was
collected. All the plasmapheresis samples were from the
first plasmapheresis run. Of the patients included, 10
AAV patients (no.1-10) were MPO-ANCA positive, six
patients (no. 11-16) were positive for both MPO-ANCA
and anti-GBM antibodies, six patients (no. 17-22) were
positive for anti-GBM antibodies without ANCA, and
five AAV patients (no. 23-27) were positive for PR3-
ANCA (Table 1). The diagnosis of AAV was according
to the Chapel Hill Consensus Conference criteria [27].
Among the above patients who were MPO-ANCA
positive and were diagnosed as AAV, 5 patients (patient
no. 1, 3, 4, 8 and 10) still had positive MPO-ANCA in
remission. The plasma samples of these 5 patients were
collected during remission.
Plasma collected from 20 healthy blood donors served
as normal control samples. All plasma samples were col-
lected at presentation and stored at -20°C until use. The
research protocol was in compliance with the Declara-
tion of Helsinki and approved by the Ethnics Committee
of Peking University First Hospital. Written inform con-
sent was obtained from each participant.
Detection of ANCA and anti-GBM antibodies
ANCA tests were performed by both indirect immuno-
fluorescence (IIF) assay and antigen-specific enzyme-
linked immunosorbent assay (ELISA). Standard IIF assay
were performed according to the manufacturer (EURO-
IMMUN, Lübeck, Germany). In antigen-specific ELISAs,
highly purified PR3 and MPO [28] were used as solid
phase ligands. Anti-GBM antibodies were detected by
ELISA as previously described [29].
Detection of the variable region glycosylation of plasma
total IgG with SNA
In brief, plates were coated with recombinant protein G
(Biovision, Mountain View, CA, USA) at 0.087 μg/ml in
0.05 mol/L bicarbonate buffer, pH 9.6, 1 hr at 37°C.
Plasma diluted 1: 3600 with 0.01 mol/L phosphate-buf-
fered saline (PBS) containing 0.1% Tween-20 (PBST)
was added to the wells in duplicate and incubated at 37°
C for 1 hr. Then biotinylated SNA (Vector Laboratories,
Burlingame, CA, USA) diluted 1: 2,000 in PBST was
a d d e df o r1h rf o l l o w e db yi n c u b a t i o nf o r1h rw i t h
alkaline phosphatase-conjugated streptavidin (Sigma, St.
Louis, MO, USA) diluted 1:2,000 in PBST. The p-nitro-
phenyl phosphate (pNPP, 1 mg/ml; Sigma) was used in
substrate buffer [1 M diethanolamine and 0.5 mM
MgCl2 (pH 9.8)]. Color development was measured
spectrophotometrically at 405 nm (Bio-Rad, Tokyo,
Japan). In each step, the volume was 100 μLa n dt h e
plates were washed three times with PBST between
steps. All samples were tested in duplicate.
Purification of IgG fractions
IgG fractions were purified by protein G affinity column
(Amersham Pharmacia, Sweden) with PBS as starting
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Page 2 of 13buffer and 0.1 mol/L glycine, pH 2.7 as eluting buffer, at
a flow rate of 1 mL/min at room temperature. IgG was
eluted and neutralized to pH 7.0 with 2 mol/L Tris-HCl,
pH 9.0 immediately, and dialyzed against PBS. To obtain
IgG-Fab and IgG-Fc fragments, purified IgG was
digested with papain (Sigma) after which the digest was
loaded onto protein A affinity column (Amersham Phar-
macia, Sweden).
Purification of autoantibodies with immunoaffinity
chromatography
In brief, IgG fractions containing anti-MPO antibodies
and anti-GBM antibodies were applied to the affinity
column coupled with purified native MPO [28] and a3
(IV)NC1 respectively. Antigen-specific fractions were
eluted with 0.05 mol/L glycine and 0.5 mol/L NaCl (pH
2.7), neutralized to pH 7.0, concentrated, and dialyzed
against PBS.
Detection of SNA binding to intact IgG, IgG-Fab and IgG-
Fc
The assay was performed as described by Dalziel et al
[21], with some minor modifications. Intact IgG, pre-
pared Fab and Fc fragments of IgG were loaded on a
SDS-polyacrylamide gel (SDS-PAGE) separately. Electro-
phoresis was performed for 40-60 min in Tris-Glycine
buffer. The proteins were transferred onto nitrocellulose
(Schleicher & Schuell, Dassel, Germany) and blocked
overnight at 4°C in PBS (pH 7.4)/0.2% Tween 20/1.0%
bovine serum albumin (PTB solution). The blot was
Table 1 General data of the patients at presentation
Patient
No.
Gender Age
(years)
Serum
autoantibodies
Organ
involvement
BVAS Titer of serum autoantibodies
(lgT)
SNA binding IgG/IgG
(%)
1 F 73 Anti-MPO+ K 10 3.20 7.80
2 M 68 Anti-MPO+ K 12 3.81 8.60
3 M 62 Anti-MPO+ K 14 2.60 6.76
4 F 15 Anti-MPO+ K 12 3.81 10.20
5 F 62 Anti-MPO+ K 16 3.51 7.75
6 F 77 Anti-MPO+ K, L 19 3.2 12.00
7 M 53 Anti-MPO+ K, L 20 3.81 12.0
8 M 72 Anti-MPO+ K, L 18 4.11 13.3
9 F 62 Anti-MPO+ K, L, G, N 22 3.81 13.1
10 M 14 Anti-MPO+ K 11 4.11 9.11
11 M 68 Anti-MPO+, anti-GBM
+
K, L 13 2.60, 2.90* 7.20
12 F 13 Anti-MPO+, anti-GBM
+
K, L, G 15 3.81, 2.60* 11.60
13 M 68 Anti-MPO+, anti-GBM
+
K, L, G, J 20 2.60, 2.90* 11.83
14 M 62 Anti-MPO+, anti-GBM
+
K, L, ENT 15 2.00, 3.20* 7.22
15 M 58 Anti-MPO+, anti-GBM
+
K, ENT 17 2.90, 3.51* 6.98
16 M 70 Anti-MPO+, anti-GBM
+
K, J, ENT 14 3.81, 2.90* 6.34
17 M 19 Anti-GBM+ K, L – 3.81 13.05
18 M 26 Anti-GBM+ K, L – 3.51 6.68
19 M 24 Anti-GBM+ K, L – 2.90 22.37
20 M 27 Anti-GBM+ K – 3.20 8.20
21 M 17 Anti-GBM+ K – 3.20 6.86
22 M 26 Anti-GBM+ K – 2.90 12.44
23 M 72 Anti-PR3+ K, L, J, ENT 18 2.00 18.68
24 M 67 Anti-PR3+ K 9 2.00 4.00
25 M 68 Anti-PR3+ K, L, J, ENT 21 2.60 6.30
26 F 21 Anti-PR3+ K, L, 16 2.00 14.7
27 M 50 Anti-PR3+ K, ENT 14 2.90 8.23
[Abbreviations] BVAS: Birmingham Vasculitis Activity Score; ENT: ear, nose and throat; G: gastrointestinal tract; J: joint; K: kidney; L: lung or respiratory system;
MPO: myeloperoxidase; N: nervous system; PR3: proteinase 3; SNA: Sambucus nigra agglutinin.
*: titer of anti-GBM antibody.
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in PTB solution), washed three times (15 min each)
with PBST, incubated for 1 hr with streptavidin-horse-
radish peroxidase (Vector, 1: 2000 dilution in PTB solu-
tion), washed three times as before, and then detected
using enhanced chemiluminescence (ECL) and light sen-
sitive film. To confirm the position of IgG, Fab and Fc
fragments, horseradish peroxidase-labeled polyclonal
goat antibodies against intact IgG (Sigma), Fab (Sigma)
and Fc (Sigma) were used instead of biotinylated SNA
after blocking. Then the same detecting procedure was
followed.
Lectin affinity chromatography
The assay was performed as described by Franco et al.
[30], with some minor modifications. IgG fractions were
applied to the affinity column coupled with SNA (Vec-
tor), at a flow rate of 0.3 mL/min, with PBS as starting
buffer. The eluted fractions were eluted with 0.5 mol/L
lactose in PBS followed by 0.5 mol/L lactose in 0.2 mol/
L acetic acid buffer (pH 3.0). The eluted fractions were
neutralized to pH 7.0, concentrated, and dialyzed against
PBS.
Detection of the antigen binding levels of non-SNA-
binding IgG and SNA-binding IgG
The assay was performed as described above, with some
minor modifications. After antigen was coated on plates,
the IgG diluted 100 μg/mL with PBST was added. Every
sample was tested in two parallel wells. All assays were
taken in duplicate.
To further confirm the influence of variable glycosyla-
tion on the antigen-binding level of IgG, the SNA-bind-
ing IgG samples were digested at 37°C for 48 hr with
neuraminidase (Sigma), which could remove the term-
inal a2, 6-linked sialic acid from the N-glycan of IgG, in
reaction buffer, pH 5.5. Alternatively, the proteins were
exposed to endoglycosidase F2 (Sigma), which could
r e l e a s et h ew h o l eN - g l y c a nf r o mt h en a t i v eI g G - F a b
[31], at 37°C for 1 hr in reaction buffer, pH 4.5.
Detection of avidity constant of non-SNA-binding IgG and
SNA-binding IgG
The avidity constant (aK) was determined as the reci-
procal value of the antigen (MPO or a3(IV)NC1) molar
concentration in the liquid phase resulting in 50% inhi-
bition of antigen-antibody binding in solid phase ELISA,
as described in our previous study [32]. Briefly, the
appropriate IgG dilution which gave an OD value of
about 0.7 in the standard ELISA was determined first
for each IgG (non-SNA-binding IgG or SNA-binding
IgG). The competitive binding assay was performed by
incubating the appropriately diluted IgG with increasing
amounts of purified antigen (0.1 mg/L-100 mg/L) in
PBST for 2 hr at 37°C. The mixture was then trans-
ferred to antigen-coated plates for the standard ELISA
procedure. All assays were performed in duplicate.
Detection of variable region glycosylation levels of total
IgG and affinity-purified autoantibodies
The assay was performed as described above, with some
minor modifications. Total IgG or purified autoantibo-
dies were diluted at 2 μg/mL in 0.05 mol/L bicarbonate
buffer, pH 9.6 and coated on plates at 37°C for 1 hr.
The following steps were the same as above from the
step in which biotinylated SNA was added. Each sample
was tested in duplicate.
Measurement of respiratory burst in neutrophils by
oxidation of dihydrorhodamine (DHR) to rhodamine
The generation of reactive oxygen radicals using DHR
was assessed as described previously [33], with some
minor modification. In brief, neutrophils (2.5 × 10
6/mL
HBSS) were incubated with cytochalasin B (5 μg/mL,
Sigma) for 5 min at 37°C to enhance the oxygen radical
production. Then, neutrophils were loaded with 0.05
mM DHR (Sigma) and 2 mM sodium azide (NaN3)a t
3 7 ° Ca n dp r i m e dw i t hT N F a (2 ng/mL) for 15 min at
37°C. The non-SNA-binding and the SNA-binding frac-
tion of anti-MPO antibodies-containing IgG and anti-
PR3 antibodies-containing IgG were added with a final
concentration of 100 μg/mL. Monoclonal mouse anti-
MPO antibody (5 μg / m L ,A b c a m ,C a m b r i d g e ,M A ,
USA) and monoclonal mouse anti-PR3 antibody (5 μg/
mL, Abcam) were used as positive controls. Then the
reaction was stopped after 60 min by addition of 3 mL
of ice-cold HBSS/1%BSA. We analyzed samples using
Calibur flow cytometer (BD FACSCalibur). Data were
collected from 20,000 cells per sample. The mean fluor-
escence intensity (MFI), representing the amount of
generated oxygen radicals, was reported. All assays were
performed in duplicate.
Statistical analysis
Quantitative data were expressed as mean ± SD and
were evaluated using t-test or one-way ANOVA analysis
as appropriate. The Pearson test was used for correla-
tion analysis. A P-value of less than 0.05 was considered
significant. Analysis was performed with SPSS statistical
software package (version 11, Chicago, IL, USA).
Results
General data of the patients
Demographic and clinical data of the patients included
are listed in Table 1. The average titer of anti-MPO
antibodies, anti-GBM antibodies and anti-PR3 antibodies
was 3.36 ± 0.64, 3.13 ± 0.35 and 2.30 ± 0.42, respec-
tively. The titer of anti-PR3 antibodies was significantly
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antibodies (P < 0.001 and P = 0.006, respectively).
Identification of binding between SNA and IgG-Fab
After incubation with papain, intact IgG was partially
digested. The resulting digest was separated into two
parts with protein A chromatography, i.e. Fab fragments
(flow-through fraction) and Fc fragments together with
undigested IgG (eluted fraction). Proper separation was
confirmed by Western blot using polyclonal mouse anti-
Fab antibodies and polyclonal mouse anti-Fc antibodies
(Figure 1). SNA mainly recognized Fab (lane 8) and
weakly recognized Fc (lane 9), as has been described
previously [20,21].
Comparison of the variable glycosylation levels of plasma
total IgG between patients and normal controls
The variable region glycosylation levels of plasma total
IgG of 20 normal controls, 10 patients with anti-MPO
antibodies (no. 1-10), 6 patients with both anti-MPO
Figure 1 Identification of the binding specificity of SNA. A: Western-blot analysis of intact IgG, IgG-Fab and IgG-Fc after papain digestion. a:
Detection with mouse polyclonal anti-Fab antibodies. Lane 1: intact IgG; lane 2: flow-through fraction of protein A-Sepharose; lane 3: eluted fraction of
protein A-Sepharose. b: Detection with mouse polyclonal anti-Fc antibodies. Lane 4: intact IgG; lane 5: flow-through fraction of protein A-Sepharose;
lane 6: eluted fraction of protein A-Sepharose. c: Detection with SNA. Lane 7: intact IgG; lane 8: flow-through fraction of protein A-Sepharose; lane 9:
eluted fraction of protein A-Sepharose. B: Comparison of variable region glycosylation levels of plasma total IgG between patients and normal controls.
Normal: 20 normal controls; group 1: 10 patients with anti-MPO antibodies; group 2: 6 patients with both anti-GBM antibodies and anti-MPO
antibodies; group 3: 6 patients with anti-GBM antibodies without anti-MPO antibodies; group 4: 5 patients with anti-PR3 antibodies.
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patients with anti-GBM antibodies (no.17-22), and 5
patients with anti-PR3 antibodies (no. 23-27) was 0.253
± 0.102, 0.256 ± 0.096, 0.215 ± 0.060, 0.238 ± 0.050 and
0.245 ± 0.088, respectively [expressed by the absorbance
value at 405 nm (A405)]. There was no significant dif-
ference in the variable region glycosylation levels of
plasma total IgG among these groups (P > 0.05) (Figure
1B).
SNA-affinity chromatography
The percentages of the SNA-binding fraction in total
IgG for the different groups were as follows: 9.23 ±
5.63% (for 5 healthy blood donors), 10.06 ± 2.39% (for
10 patients with anti-MPO antibodies), 8.53 ± 2.49%
(for 6 patients with both anti-GBM antibodies and anti-
MPO antibodies), 11.60 ± 5.95% (for 6 patients with
anti-GBM antibodies and without anti-MPO antibodies)
and 10.38 ± 6.11% (for 5 patients with anti-PR3 antibo-
dies). There was no significant difference in the percen-
tage of the SNA-binding fraction in total IgG among
these groups (P = 0.575).
Comparison of antigen-binding levels between non-SNA-
binding IgG and SNA-binding IgG
For anti-MPO antibodies-containing IgG (patients no. 1-
16), the binding level to MPO of non-SNA-binding frac-
tions was significantly lower than that of SNA-binding
fractions at the same concentration of IgG (0.572 ±
0.590 vs. 0.962 ± 0.670, P < 0.001). For anti-PR3 antibo-
dies-containing IgG (patients no. 23-27), the binding
level to PR3 of non-SNA-binding fractions was signifi-
cantly lower than that of SNA-binding fractions at the
same concentration of IgG (0.362 ± 0.530 vs. 0.560 ±
0.531, P = 0.003). For anti-GBM antibodies-containing
IgG (patients no. 10-22), the binding level to a3(IV)NC1
of non-SNA-binding fractions was significantly higher
than that of SNA-binding fractions at the same concen-
tration of IgG (1.301 ± 0.594 vs. 1.172 ± 0.583, P =
0.044) (Figure 2A).
Since anti-GBM antibodies mainly recognize two
regions on a3(IV)NC1 (EA,r e s i d u e s1 7t o3 1a n dE B,
residues 127 to 141) [34], we compared the antigen
binding levels to recombinant EA and EB [35] between
non-SNA-binding IgG and SNA-binding IgG of patients
with positive anti-GBM antibodies. As shown in Figure
2B, the binding level to EA of non-SNA-binding frac-
tions was significantly higher than that of SNA-binding
fractions (1.462 ± 0.230 vs. 1.060 ± 0.431, P < 0.001),
while the binding level to EB of non-SNA-binding frac-
tions was similar to that ofS N A - b i n d i n gf r a c t i o n s
(0.923 ± 0.265 vs. 0.879 ± 0.325, P > 0.05).
After SNA-binding IgG was treated with neuramini-
dase, there was no significant change in antigen-binding
level (Figure 2C). However, when SNA-binding IgG was
treated with endoglycosidase F2, the binding level to
MPO of anti-MPO antibodies-containing IgG and the
binding level to PR3 of anti-PR3 antibodies-containing
IgG decreased (P = 0.022 and P = 0.031, respectively),
while the binding level to a3(IV)NC1 of anti-GBM anti-
bodies-containing IgG increased (P = 0.042) (Figure 2D).
Comparison of the avidity constant between non-SNA-
binding IgG and SNA-binding IgG
Patients no. 11-16 who had both anti-MPO antibodies
and anti-a3(IV)NC1 antibodies were included in this
analysis. As shown in Figure 3, the MPO-binding level
of non-SNA-binding IgG was lower than that of SNA-
binding IgG for all 6 patients, while the MPO-binding
avidity constant of non-SNA-binding IgG was lower
than that of SNA-binding IgG in 5 out of 6 patients.
The a3(IV)NC1-binding level of non-SNA-binding IgG
was higher than that of SNA-binding IgG for all 6
patients, while the a3(IV)NC1-binding avidity constant
of non-SNA-binding IgG was higher than that of SNA-
binding IgG in 3 out of 6 patients.
Effects of non-SNA-binding ANCA-IgG and SNA-binding
ANCA-IgG on respiratory burst induction in neutrophils
Ten patients with anti-MPO antibodies (patient no. 1-
10), 4 patients with both anti-MPO antibodies and anti-
GBM antibodies (patient no. 12-15) and 5 patients with
anti-PR3 antibodies (patient no. 23-27) were enrolled in
this analysis. In the absence of IgG, the baseline level of
the respiratory burst of neutrophils was 586.50 ± 28.21
(expressed by MFI). Moreover, IgG of a healthy blood
donor did not significantly activate oxygen radical pro-
duction in neutrophils irrespective of the variable region
glycosylation status. Both monoclonal mouse anti-MPO
antibody and anti-MPO antibodies-containing IgG of
patients enhanced the respiratory burst of neutrophils.
Compared with the non-SNA-binding fractions of anti-
MPO antibodies-containing IgG, the SNA-binding frac-
tions induced a significantly higher level of the respira-
tory burst of neutrophils (1025.14 ± 322.09 vs.8 4 3 . 0 0±
326.36, P < 0.001) (Figure 4A). Similar results were
obtained when comparing then o n - S N A - b i n d i n gf r a c -
tions of anti-PR3 antibodies-containing IgG and the
SNA-binding fractions for respiratory burst induction in
neutrophils (1218.60 ± 414.62 vs. 817.80 ± 105.14, P =
0.043) (Figure 4B).
Antigen-specific IgG separation with immunoaffinity
chromatography
The percentage of purified anti-MPO antibodies in total
IgG from patient no. 1-16 was 1.53 ± 0.66%. The per-
centage of the purified anti-a3(IV)NC1 antibodies in
total IgG from patient no. 11-22 was 1.06 ± 0.55%.
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groups (P = 0.838).
Comparison of levels of variable region glycosylation
between total IgG and antigen-specific IgG
The variable region glycosylation level of total IgG from
MPO-ANCA positive patients was comparable to that of
total IgG from 5 healthy donors (A405, 1.021 ± 0.201 vs.
1.107 ± 0.326, P > 0.05), but was significantly lower than
that of affinity-purified anti-MPO antibodies (1.021 ±
0.201 vs. 1.434 ± 0.134, P = 0.004). The variable region
glycosylation level of total IgG from anti-GBM antibody
positive patients was also comparable to that of total
IgG from 5 healthy donors (1.034 ± 0.340 vs. 1.107 ±
0.326, P > 0.05), but was significantly higher than that
of affinity-purified anti-GBM antibodies (1.034 ± 0.340
vs. 0.734 ± 0.333, P = 0.007) (Figure 5A).
Then the results were further confirmed with Western
blot analysis. Six patients who had both anti-MPO
antibodies and anti-GBM antibodies (patient no. 11-16)
were included in this analysis. Total IgG, purified anti-
MPO antibodies and purified anti-GBM antibodies of
these patients were mixed respectively and were ana-
lyzed in Western blot analysis. As shown in Figure 5B,
the level of variable glycosylation of mixed total IgG was
lower than that of mixed purified anti-MPO antibodies,
but was higher than that of mixed purified anti-GBM
antibodies.
Correlation between levels of variable glycosylation of
anti-MPO antibodies and clinical parameters
Correlation analysis was performed for patients no. 1-10
who were MPO-ANCA positive but negative for anti-
GBM antibodies. No correlation between the levels of
variable region glycosylation of affinity-purified MPO-
ANCA and the titers of MPO-ANCA was found (r =
0.149, P = 0.682). No correlation between the level of
variable region glycosylation of affinity-purified MPO-
Figure 2 Comparison of antigen-binding levels between non-SNA-binding IgG and SNA-binding IgG. A: Comparison of binding levels to
MPO, a3(IV)NC1 and PR3 between non-SNA-binding IgG and SNA-binding IgG. Open squares represented non-SNA-binding IgG; Filled squares
represented SNA-binding IgG. B: Comparison of binding levels to a3(IV)NC1, EA and EB between non-SNA-binding IgG and SNA-binding IgG.
Open squares represented non-SNA-binding IgG; Filled squares represented SNA-binding IgG. C: Influence of neuraminidase treatment on the
antigen-binding levels of SNA-binding IgG. Filled squares: before treatment; gray squares: after treatment D: Influence of endoglycosidase F2
treatment on the antigen-binding levels of SNA-binding IgG. Filled squares: before treatment; gray squares: after treatment.
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total IgG was found (r = 0.628, P = 0.052). However, the
level of variable region glycosylation of affinity-purified
MPO-ANCA correlated with Birmingham Vasculitis
Activity Score (BVAS) [36] (r = 0.641, P = 0.046) (Figure
5C). The number of PR3-ANCA positive patients was to
low for correlation analysis.
Comparison of variable region glycosylation of anti-MPO
antibodies between patients with active AAV and in
remission
Plasma samples of 5 patients (patient no. 1, 3, 4, 8 and
10) who had positive MPO-ANCA in the remission
stage of AAV were obtained.. As shown in Figure 6, the
percentage of the purified MPO-ANCA in total IgG was
significantly higher in active phase than the same
patients in remission (1.386 ± 0.624% vs. 0.487 ±
0.332%, P = 0.013). The antigen-binding level of affinity-
purified MPO-ANCA was significantly higher in active
phase than the same patients in remission (1.473 ±
0.359 vs. 0.599 ± 0.321, P = 0.009). The level of variable
region glycosylation of affinity-purified MPO-ANCA
was significantly higher in active phase than the same
patients in remission (1.414 ± 0.109 vs. 1.217 ± 0.110, P
= 0.001).
Discussion
Previous studies on the variable region glycosylation of
IgG have been performed mainly on monoclonal antibo-
dies from animals or total IgG from healthy individuals
[37,38]. To our knowledge, our study is the first investi-
gation on the glycosylation status of the variable region
of disease-associated antigen-specific IgGs. Previous stu-
dies by Holland et al. [25] have shown that while the
oligosaccharides released from ANCA-containing IgG-
Fc were hypogalactosylated and hyposialylated, those
released from IgG-Fab were normally galactosylated and
sialylated. In this study the authors did not report any
difference in variable region glycosylation between
ANCA-containing IgG and normal IgG upon analysis of
total serum-derived IgG. In the current study, when we
compared the variable region glycosylation levels of total
Figure 3 Comparison of avidity constant of anti-MPO and anti-a3(IV)NC1 antibodies between non-SNA-binding IgG and SNA-binding
IgG. A and B: Comparison of antigen-binding levels of anti-MPO antibodies and anti-a3(IV)NC1 antibodies between non-SNA-binding IgG and
SNA-binding IgG. C and D: Comparison of avidity constant of anti-MPO antibodies and anti-a3(IV)NC1 antibodies between non-SNA-binding IgG
and SNA-binding IgG. Open squares represent non-SNA-binding IgG; Filled squares represent SNA-binding IgG.
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no significant difference was found either. However, affi-
nity-purified anti-MPO antibodies were found to have a
significantly higher level of variable region glycosylation
than total IgG, while purified anti-GBM antibody was
found to have a significantly lower level of variable
region glycosylation than total IgG.
In the current study, incubation with neuraminidase
did not significantly change the antigen-binding ability
of SNA-binding IgG, while incubation with endoglycosi-
dase F2 significantly changed the antigen-binding ability
of SNA-binding IgG. It indicated that the variable region
glycan molecule, but not the terminal sialic acid, influ-
enced the antigen-binding ability of autoantibodies It
also indicated that electrostatic forces are not a major
determinant, because the isoelectric point of a3(IV)NC1
(calculated isoelectric point 8.9 [39]) is between the
isoelectric points of MPO and PR3 (11.0 and 7.9 for
MPO and PR3, respectively [40,41]). How oligosacchar-
ides in the variable region influence antigen-antibody
binding is not clear yet. In a previous study, it was pro-
p o s e dt h a to l i g o s a c c h a r i d e si n the variable region affect
the antigen-binding ability by influencing hydrophilic
interactions between the antibody and antigen [42].
Amino acid sequences of the variable regions of IgG are
highly variable and are influenced by a number of fac-
tors. Initially, the rearrangement of VH and VL genes
occurs in the bone marrow. Then after B cells encoun-
ter antigen, the somatic mutation machinery is activated
in the germinal center [43]. Interestingly, sequence ana-
lysis has shown that there is no potential N-linked gly-
cosylation site [Asn-X-Ser/Thr (X is any amino acid
except Pro, Asp or Glu)] in germline V sequences, sug-
gesting that variable region glycosylation sites mainly
Figure 4 Comparison of effects on respiratory burst of neutrophils between non-SNA-binding IgG and SNA-binding IgG. A: Respiratory
burst of neutrophils induced by anti-MPO antibodies. Mo: monoclonal mouse anti-MPO antibody. N: normal IgG. Because of limited sample
volume, two patients with anti-MPO antibodies and anti-GBM antibodies (patients 11 and 16) were not included in this analysis. Open squares
represent non-SNA-binding IgG; Filled squares represent SNA-binding IgG. B: Respiratory burst of neutrophils induced by anti-PR3 antibodies. Mo:
monoclonal mouse anti-PR3 antibody. N: normal IgG. Open squares represent non-SNA-binding IgG; Filled squares represent SNA-binding IgG.
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linked glycosylation site in the variable region is gener-
ated during the process of affinity maturation [47], we
speculate that the type of antigen is one of the determi-
nants of oligosaccharide distribution in the variable
region of the antibody. Moreover, since the oligosac-
charide distribution of the variable region can influence
the antigen-antibody binding, it could also influence the
process of affinity maturation of the antibody. We spec-
ulate that if a variable region sequence, with or without
potential glycosylation sites, has higher affinity for an
antigen, this sequence will most likely be amplified dur-
ing affinity maturation.
It has been suggested that hyposialylation of the
ANCA antibody Fc part increases the ability of ANCA
to induce the respiratory burst in neutrophils [7]. In the
present study, we showed that ANCA IgG with a high
level of variable region glycosylation had a higher avidity
constant and an increased ability to induce the respira-
tory burst in neutrophils. Furthermore, the level of
Figure 5 Comparison of levels of variable glycosylation between total IgG and affinity-purified autoantibodies. A: Comparison of levels
of variable region glycosylation between total IgG and purified autoantibodies in ELISA. Group a: healthy controls. Open squares represent total
IgG. Group b: patients with positive anti-MPO antibodies. Open squares represent total IgG; Filled squares represent affinity-purified anti-MPO
antibodies. Group c: patients with positive anti-GBM antibodies. Open squares represent total IgG; Filled squares represent affinity-purified anti-a3
(IV)NC1 antibodies. B: Comparison of levels of variable glycosylation between total IgG and purified autoantibodies by Western-blot analysis. The
concentration of all samples was 1 μg/mL. Lane 1: mixture of affinity-purified anti-MPO antibodies from patient 11-16; lane 2: mixture of total
IgG from patient 11-16; lane 3: mixture of affinity-purified anti-a3(IV)NC1 antibodies from patient 11-16. C: Correlation between the levels of
variable glycosylation of anti-MPO antibodies and BVAS.
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Page 10 of 13Figure 6 Comparison of immune characteristics of anti-MPO antibodies between AAV patients in active phase and in remission.A :
Comparison of percentage of affinity-purified anti-MPO antibodies in total IgG between AAV patients in active phase and in remission. B:
Comparison of antigen-binding levels of affiniy-purified anti-MPO antibodies between AAV patients in active phase and in remission. C:
Comparison of levels of variable region glycosylation of affiniy-purified anti-MPO antibodies between AAV patients in active phase and in
remission.
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correlated with disease activity. Moreover, MPO-ANCA
from patients in remission demonstrated a significantly
lower level of variable region glycosylation compared to
MPO-ANCA from patients with active disease. These
results suggest that the level of variable region glycosyla-
tion of ANCA might be a potent biomarker reflecting
disease activity in AAV.
Conclusions
In conclusion, the characteristics of variable region gly-
cosylation of ANCA and anti-GBM antibodies were dif-
ferent from that of total IgG, which might influence the
antigen-binding ability of these antibodies. Variable
region glycosylation of ANCA might influence the effect
of ANCA-induced neutrophils respiratory burst.
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